AC
SLXP

Addison Capital’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Addison Capital’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,201
Closed -$253K – 104
2014
Q4 		$253K Buy
+2,201
New +$267K 0.21% 70

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Addison Capital's SLXP Position: Q1 2015 in Review

Addison Capital sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 2,201 shares — an estimated $253K sold.

Addison Capital first reported a position in SLXP in Q4 2014 and held it in 1 quarter. The position peaked at $253K in Q4 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

  • Addison Capital reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
  • Addison Capital sold 2,201 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $253K.
  • Addison Capital first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q4 2014 and held it in 1 quarter.
  • Addison Capital's SALIX PHARMACEUTICALS LTD DEL position peaked at $253K in Q4 2014.
  • 298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Addison Capital's 13F filing for Q1 2015, filed 12 May 2015.